ARS Pharmaceuticals (SPRY) Prepaid Assets (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Prepaid Assets of $6.8 million for Q1 2026, up 9.59% sequentially from $6.2 million in Q4 2025, and down 41.28% YoY from $11.6 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Prepaid Assets (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Prepaid Assets for 7 years, with the latest figure at $6.8 million in Q1 2026.
- Quarterly Prepaid Assets fell 41.28% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (down 41.28% YoY) and the FY2025 annual result came in at $6.2 million, down 10.05% from the prior year.
- Prepaid Assets rose to $6.8 million in Q1 2026 per SPRY's latest filing, from $6.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $11.6 million in Q1 2025 and troughed at $137000.0 in Q3 2024.
- A 5-year average of $3.8 million and a median of $3.3 million in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets sank 86.75% in 2024, then jumped 4586.86% in 2025.
- Over 5 years, Prepaid Assets stood at $3.3 million in 2022, then tumbled by 66.13% to $1.1 million in 2023, then surged by 512.63% to $6.9 million in 2024, then decreased by 10.05% to $6.2 million in 2025, then increased by 9.59% to $6.8 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $6.8 million, $6.2 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.14 Mn |
| Mar 31, 2026 | 6.79 Mn |
| Dec 31, 2025 | 6.19 Mn |
| Sep 30, 2025 | 6.42 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 11.56 Mn |
| Dec 31, 2024 | 6.89 Mn |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 465,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 866,000.00 |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 4.18 Mn |
| Jun 30, 2022 | 5.15 Mn |
| Mar 31, 2022 | 7.49 Mn |
| Dec 31, 2021 | 666,000.00 |
| Sep 30, 2021 | 4.70 Mn |